Vivimusta 25 MG/ML Injectable Solution
- RxCUI
- 2622914
- RxNorm name
- Vivimusta 25 MG/ML Injectable Solution
- Display name
- Vivimusta 25 MG/ML Injectable Solution
- Full name
- Vivimusta 25 MG/ML Injectable Solution
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:21
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VIVIMUSTA | BENDAMUSTINE HYDROCHLORIDE | Azurity Pharmaceuticals, Inc. | 4df6548f-c4ad-4eb2-a54f-19766a3d90ca | 2025-04-03 | Warnings, Adverse reactions | 2622914 |
| VIVIMUSTA | BENDAMUSTINE HYDROCHLORIDE | Slayback Pharma LLC | cbcc6eb7-aa62-4599-af49-05203fedb4bb | 2024-02-27 | Warnings, Adverse reactions | 2622914 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| cbcc6eb7-aa62-4599-af49-05203fedb4bb | VIVIMUSTA 25 MG/ML Injectable Solution [PSN] · bendamustine hydrochloride 25 MG/ML Injectable Solution [Vivimusta] [SBD] · Vivimusta 25 MG/ML Injectable Solution [SY] | 3 | 22 | These highlights do not include all the information needed to use VIVIMUSTA safely and effectively. See full prescribing information for VIVIMUSTA. VIVIMUSTA® (bendamustine hydrochloride injection), for intravenous use. Initial U.S. Approval: 2008 | 20240227 |
| 4df6548f-c4ad-4eb2-a54f-19766a3d90ca | VIVIMUSTA 25 MG/ML Injectable Solution [PSN] · bendamustine hydrochloride 25 MG/ML Injectable Solution [Vivimusta] [SBD] · Vivimusta 25 MG/ML Injectable Solution [SY] | 3 | 2 | These highlights do not include all the information needed to use VIVIMUSTA safely and effectively. See full prescribing information for VIVIMUSTA. VIVIMUSTA® (bendamustine hydrochloride injection), for intravenous use. Initial U.S. Approval: 2008 | 20250403 |